Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Efficacy and Safety of Nutraceuticals (Bergamot 450 mg, Gymnema (400 mg, Phaseolamin 30 mg, Olea Europaea 10 mg) in Patients With Diabetes Mellitus Type II and Dyslipidemia.
The presence of dyslipidemia, is a significant cardiovascular risk factor. This factor,
however, determines the three-fold increase in cardiometabolic risk when an isolated or mixed
dyslipidemia is associated with the presence of diabetes mellitus. Diabetes mellitus is a
metabolic alteration resulting in a decrease in insulin secondary to reduced availability of
this hormone or an impediment to its normal action or a combination of these factors. . Under
normal conditions, the vascular endothelium responds to short-term increases in flow by
releasing NO and other endothelium-dependent relaxing factors that dilate the artery.
Flow-mediated dilation(FMD) is impaired in atherosclerotic coronary arteries. The
supplementation with polyphenols of olive leaves, bergamot extract, gymnema sylvatic extract
(gymnemic acid) and phaseolamin (bean protein) significantly improves the glico-lipid balance
through an improvement in liver function, an inhibition to more levels of lipid metabolism .
Recently, it has been documented how the polyphenolic fraction extracted from bergamot (BPF)
administered orally both in animal models with induced hyperlipidemia diet, and in patients
with metabolic syndrome, produces a significant and substantial reduction of serum
cholesterol, triglycerides and blood levels of glucose. This effect was accompanied by an
important improvement in vascular reactivity in patients with hyperlipidemia and high blood
sugar, suggesting the potential protective role of BPF in patients with metabolic syndrome
and elevated cardiovascular risk.
Oleuropeina (Olea Europaea) is also characterized by a peculiar polyphenolic profile. Both
fruits and leaves, thanks to their cardioprotective activity, are used as antihypertensive
agents and in the treatment of vascular disorders. The gymnemic acid (glycosidic triterpene),
extracted from the leaves of Gymnema Sylvestre, is the representative element of the plant.
Thanks to its presence in the phytocomplex, it carries out a hypoglycaemic action through two
main mechanisms: inhibition of intestinal sugar absorption and increased metabolic
transformation of glucose at the cellular level.
To better define the interrelations of systemic CRFs, FMD, and effects of chronic
nutraceutical supplements we performed clinical evaluations and ultrasound measurements of
the flow and diameter responses to forearm cuff occlusion in a large, well characterized
community-based cohort.
Primary end point Effectiveness To demonstrate in diabetic patients,the effectiveness of
nutraceuticals (bergamot 450 mg, Gymnema (400 mg, Phaseolamin 30 mg, Olea Europaea 10 mg) to
reduce total and LDL cholesterol.
Secondary end points To demonstrate in diabetic patients,the effectiveness of nutraceuticals
(bergamot 450 mg, Gymnema (400 mg, Phaseolamin 30 mg, Olea Europaea 10 mg) to improve
Endothelial function evaluated with vascular Doppler color echo; CHARACTERISTICS OF THE
POPULATION diabetic patients in optimized medical therapy and increased plasma levels of
total and LDL cholesterol EXPERIMENTAL DESIGN AND METHODOLOGY OF RESEARCH Experimental
drawing Phase II prospective, randomized, comparative, vs placebo study Sample size
Literature data show that total cholesterol levels> 200 mg / dl and LDL> 130 mg//dl have an
increased cardiovascular risk in subjects with diabetes mellitus; in the Calabrian people the
Health Examination Survey conducted in 2012, showed the following average values: total
cholesterolemia 233 +/- 45 mg /dl for men and 238 +/- 40 mg / dl for women; while for LDL
cholesterol the mean values are respectively 151 +/- 30 mg / dl in humans and 148 +/- 35 mg /
dl in women. In these subjects the doubling of the statin dosage contributes to a further
reduction of plasma levels by about 6%; the hypothesis not evaluated is that the integration
with nutraceuticals (bergamot 450 mg, Gymnema (400 mg, Phaseolamin 30 mg, Olea Europaea 10
mg) in patients with optimized therapy, involves reduction of plasma levels> 6% HYPOTHESIS N
=2(1600)/(196)*6,2= 3200/196*6.2= 88 The study will be performed with the enrollment of 88
diabetic patients, Eligible patients will be of both sexes, and naïve patients on
nutraceutical (920 mg), consequently recruited.
Patients using randomization tab will be randomized 1: 1 to treatment with active substance
versus placebo. Investigators may not be aware of the sequence in which the treatments will
be assigned nor foresee the next assignment in any way.
TIMING OF THE STUDY The duration of the study will be 12 weeks after recruitment. After
signing the informed consent, previously approved by the Ethics Committee, the subjects can
fully enter the study. Each patient must make three visits: SEL (selection visit); V01
(initial visit); TERM (final visit). Excluding the patient's inclusion visit (V01), each
visit will take place in the morning and each patient will be studied at the same time of
day, between 8.00 am and 12.00 am, during the study (± 2 hours).
The treatment is always accompanied by main meals. The first administration in naïve patients
on Nutraceuticals will be done under the supervision of the staff involved in the study.
Patients will then be reviewed at 4 and 12 weeks after recruitment.
ANALYTICAL PRESENTATION OF THE PROCEDURES TO BE PERFORMED Before signing informed consent,
patients will be informed about the rationale of the study, the objective and the procedures
of the study itself. All the subjects can refuse to participate, or they can interrupt the
participation at any time.
The study will be conducted in accordance with the protocol, Good Clinical Practice (GCP) and
according to the regulatory principles of application.
Selection visit During the selection visit (SEL), all patients are subjected to the following
evaluation.
- Collection of informed consent by the principal investigator;
- Complete medical documentation on anthropological characteristics and clinical anamnesis
(including any chronic treatments, or in the case of women, of contraceptive measures),
and assessment of the presence of inclusion and exclusion criteria;
- Data collection: weight, height, Body Mass Index calculation, Systolic Blood Pressure
and Diastolic Blood Pressure measurements (mean arterial pressure) using automatic
meters, and 12-lead electrocardiogram;
- Blood chemistry tests (total ,LDL and HDL cholesterol, glycemia, triglycerides,
creatinine, Glutamic Oxaloacetic Transaminase(GOT), Glutamic Piruvate Transaminase
(GPT), , potassium(K), Sodium (Na) uricemia and blood count, hb glycated blood sugar,
C-reactive Protein );
- Electrocardiogram
- cardiac Eco-color - doppler (evaluation of the systolic and diastolic function indices)
- Non-invasive study of endothelial function (vascular arterial Doppler )
- Ergometric test
- Six minutes walking test
- Questionnaire on quality of life SF 36
- Pregnancy test in women of childbearing age
All laboratory results and pregnancy tests are checked before enrolling the patient in the
study:
If the result of these evaluations:
A) Does not meet the inclusion criteria, the investigator must:
- Document all the interview and the occurrence of adverse events;
- Draw up the examination and a physical exam including weight, height and measurements of
systolic and diastolic pressures;
- Examine all the results of blood chemistry and biochemical tests; Document the reasons
why the patient is not included in the study. Complete the CRF (case report Forms) of
the trial. B) Satisfy the inclusion criteria (and if exclusion criteria do not appear),
a blood sample will be collected.
Therefore, the patients eligible for the study will be recruited and treated with:
- nutraceuticals (bergamot 450 mg, Gymnema (400 mg, Phaseolamin 30 mg, Olea Europaea 10
mg)
- Placebo Patients will take part in the study by double daily administration, before main
meals. The first administration always takes place in the presence of personnel involved
in the study VISIT 1 (4 WEEKS) Patients enrolled are promptly informed on the dosage of
treatment, on compliance with treatment and on the need to evaluate its effectiveness
after four weeks (± 3 days): V01.
During the 4-week visit (V01), patients undergo:
- Collection of any symptoms related to gastrointestinal disorders
- Blood sampling: Blood chemistry tests (total cholesterol, LDL and HDL cholesterol,
glycemia, triglycerides, creatinine, GOT , GPT, Na, K, uricemia and blood count, hb
glycated blood sugar, insulin, CrP )
- Objective examination
- Detection of vital parameters (blood pressure, heart rate)
- Interview on adverse events, if present, and concomitant changes to the assumption of
treatment
- Restitution of the drug and calculation of unused capsules to assess patient compliance
- Reporting in the CRF of the number of unused and returned capsules
- Delivery of the drug. FINAL VISIT (TERM)
During the final visit (TERM), made twelve weeks after enrollment (± 3 days), patients
undergo the evaluation of:
- Data collection: weight, height, BMI calculation, SBP and DBP measurements (mean
arterial pressure) using automatic meters, and twelve-lead electrocardiogram;
- Blood chemistry tests (total cholesterol, LDL and HDL cholesterol, glycemia,
triglycerides, creatinine,GOT, GPT, Na, K, uricemia and blood count, hb glycated blood
sugar, insulin,CrP)
- Electrocardiogram
- Cardiac Eco-color doppler (evaluation of the indices of systolic and diastolic function)
- Non-invasive study of endothelial function (vascular arterial Doppler)
- Ergometric test
- Six minutes walking test
- Questionnaire on quality of life SF 36
- Collection of any symptoms related to gastrointestinal disorders
- Interview on adverse events, if present, and concomitant changes to the assumption of
treatment
- Restitution of the drug and calculation of unused capsules to assess patient compliance
- Reporting in the CRF of the number of unused and returned capsules. EARLY TERMINATION OF
THE STUDY After informing the Ethics Committee and the Health Authorities, the person
who took part in the study may decide to stop the study before the deadline.
Two copies of the written consent will be dated and signed by the investigator. All data will
be collected in the case report (CRF) INTERRUPTION OF THE TREATMENT Withdrawal and
interruption of a patient's study A patient can withdraw from the study at any time.
The treatment may be prematurely and permanently interrupted by the investigator for one or
more of the following reasons:
- Patient refusal to continue the study
- Principle of an adverse event, which represents an important risk to the patient
according to the investigator or requires the prescription of treatments that are not
considered concomitant in the protocol.
- Treatment not tolerated
- Any clinical event that requires treatment interruption.
- Any clinical event that requires a type of treatment that is incompatible with the
study.
- Pregnancy Procedures
In case of premature interruption of treatment:
- the investigator must document the reason (s) and the exact time of the interruption of the
study in the CRF and in the patient's record. If more than one reason is given, the
investigator must indicate the main one.
In the case of a premature withdrawal from the study due to an adverse event (an event
requiring immediate notification or not), the investigator must collect all the information
related to the event. If necessary, the information is put together later.
- During the final follow-up visit, the investigator must:
- Draw up the interview on the occurrence of an adverse event and on the changes in the
treatment and the respective doses;
- Perform objective examination (including weight, height, systolic and diastolic blood
pressure);
- Perform a twelve-lead ECG
- Carry out a withdrawal for renal and hepatic function, possibly fasting blood count;
- Recover the remaining capsules and report in the CRF the number of unused and returned
capsules;
- Document the date of the first and last administration taken;
- Estimate patient compliance with treatment between the final and previous visits.
ADVERSE EVENTS AND ADVERSE REACTIONS Serious adverse event and adverse drug reactions The
European legislation on pharmacovigilance was amended with the adoption in 2010 of EU
Regulation 1235/2010, whose application is operational from 2 July 2012, and of Directive
2010/84 / EU, in force since 21 July 2012.
Collection and notification, by the individual Investigators and by the Promoter, of adverse
events / adverse reactions occurred to patients enrolled in clinical trials with medicinal
products for human use. For the definition of serious and non-serious adverse events, refer
to the Standards of Good Clinical Practice of the PATIENT TREATMENTS Treatment management
There is only one treatment period, and the formulation of the drug is in capsule form. The
treatment is provided directly by the investigator at the end of each scheduled visit.
Patients will take the product in a single daily dose after one of the main meals.
Delivery of treatment
Patients will be divided into two groups:
Group 1 composed of 45 enrolled subjects who will receive placebo bis in die, twenty minutes
before the main meals; Group 2 composed of 45 subjects enrolled with type II diabetes
mellitus and hypercholesterolemia without hypertriglyceridemia who will receive a double
administration of nutraceuticals (bergamot 450 mg, Gymnema (400 mg, Phaseolamin 30 mg, Olea
Europaea 10 mg) mg with the cadences described for group 1; Previous and concurrent
treatments All details on previous and concurrent treatments must be collected by the
investigator in an appropriate form in the CRF. It will be the duty of the investigator to
always evaluate that concomitant and / or previous treatments are authorized and included in
the inclusion criteria.
STATISTICAL ANALYSIS All values are expressed as mean +/- Standard deviation. The values of
the selected variables in perspective mode will be expressed as mean +/- standard deviation
(parametric variables) or median (non parametric variables). To compare the differences
between the study groups, correlation analysis, t-test for samples, independent, chi-square
test, frequency tables, cross tables and tables for multiple / dichotomous responses will be
used. A probability value <0.05 will be considered statistically significant.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |